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IMPORTANCE Difference in breast cancer survival by race is a recognized problem among
Medicare beneficiaries.
OBJECTIVE To determine if racial disparity in breast cancer survival is primarily attributable to
differences in presentation characteristics at diagnosis or subsequent treatment.
DESIGN, SETTING, AND PATIENTS Comparison of 7375 black women 65 years and older
diagnosed between 1991 to 2005 and 3 sets of 7375matched white control patients selected
from 99 898white potential controls, using data for 16 US Surveillance, Epidemiology and
End Results (SEER) sites in the SEER-Medicare database. All patients received follow-up
through December 31, 2009, and the black case patients were matched to 3 white control
populations on demographics (age, year of diagnosis, and SEER site), presentation
(demographics variables plus patient comorbid conditions and tumor characteristics such as
stage, size, grade, and estrogen receptor status), and treatment (presentation variables plus
details of surgery, radiation therapy, and chemotherapy).
MAINOUTCOMESANDMEASURES 5-Year survival.
RESULTS The absolute difference in 5-year survival (blacks, 55.9%; whites, 68.8%) was 12.9%
(95% CI, 11.5%-14.5%; P < .001) in the demographics match. This difference remained
unchanged between 1991 and 2005. After matching on presentation characteristics, the
absolute difference in 5-year survival was 4.4% (95% CI, 2.8%-5.8%; P < .001) and was 3.6%
(95% CI, 2.3%-4.9%; P < .001) lower for blacks than for whites matched also on treatment. In
the presentationmatch, fewer blacks received treatment (87.4% vs 91.8%; P < .001), time
from diagnosis to treatment was longer (29.2 vs 22.8 days; P < .001), use of anthracyclines
and taxols was lower (3.7% vs 5.0%; P < .001), and breast-conserving surgery without other
treatment was more frequent (8.2% vs 7.3%; P = .04). Nevertheless, differences in survival
associated with treatment differences accounted for only 0.81% of the 12.9% survival
difference.
CONCLUSIONS AND RELEVANCE In the SEER-Medicare database, differences in breast cancer
survival between black and white women did not substantially change among women
diagnosed between 1991 and 2005. These differences in survival appear primarily related to
presentation characteristics at diagnosis rather than treatment differences.
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F or20yearshealthcare investigators inUnitedStateshavebeenkeenlyawareof racialdisparities in survival amongwomenwithbreastcancer.1-4Numerousreportshavenot
only identified anddocumentedworse outcomes in black pa-
tients with breast cancer5-7 but have suggested potential rea-
sons for the disparities based on differences in screening,5,8,9
presentation,5,10 comorbid conditions onpresentation,5,10 tu-
mor biology,5,11,12 stage,5,6 treatment,5,13,14 and socioeco-
nomic status.7,15
This study examined the extent of the racial disparity in
breast cancer survival in the Medicare population, with the
main goal of addressing why the disparity exists. The analy-
sis usedmatching to compare the entire population of blacks
in the Surveillance, Epidemiology and End Results (SEER)–
Medicare database to 3white populations individually paired
to the black population to answer questions about the origins
of the racial disparity, specifically, (1) are white women who
present like blackwomen treated in the samewayas blackpa-
tients, and if not, (2) towhat extent does a difference in treat-
ment explain the disparity in survival?
This study also examined themagnitude of the disparity;
whether the disparity changed between the era before intro-
duction of taxanes (1991-1998) and the era after introduction
of taxanes (1999-2005); the relative contributions of presen-
tation at diagnosis, and treatment after presentation, to dif-
ferences in survival experiencedby these groups; andhowso-
cioeconomic variables relate to the overall disparity.
Methods
Patient Population
The research protocol was approved by the institutional re-
viewboard of TheChildren’sHospital of Philadelphia.We ob-
tained theSEER-Medicaredatabase for theyears 1991-2005 for
16 SEER sites throughout the United States. For each patient,
the entire SEER data set16,17 was merged with Medicare Part
A, Part B, outpatient claims, and the Social Security denomi-
nator file,whichwasupdatedDecember 31, 2009, for this data
set, providing a minimum of 4 years of follow-up for all pa-
tients.
For all analyses of trends over time, we analyzed the 12
SEERsites collectingdataover theentire spanof the study.For
analysesnot considering trendsover time,weusedall 16 sites.
Defining Patient Characteristics
We defined race using the SEER algorithm18 and compared
blackorAfricanAmericanwithwhitenon-Hispanic andwhite-
Hispanic together for the primary analysis (resultswere simi-
lar if only non-Hispanic white patients were used as controls,
because Hispanic white patients comprised only 3.8% of the
total white population and because never more than 4.6% of
anysetofmatchedpairs includedHispanicwhites). Patient co-
morbid conditions such as congestive heart failure, diabetes,
past acutemyocardial infarction, stroke, hypertension, and21
other conditions noted in the eAppendix (Supplement) were
definedwith International Classification ofDiseases,NinthRe-
vision,ClinicalModificationcodes19-22 andcollected fromMedi-
care claims (inpatient, outpatient, and physician bills) during
a 3-month period prior to diagnosis.
Tumor Biology
Patient tumor characteristics, including stage, size, grade, es-
trogen receptor status, number of nodes dissected, and num-
ber of positive nodes, were obtained through the SEER data-
base.
Treatment Variables
Wedefinedtreatmentbasedon information fromMedicareand
SEER data. Surgery and chemotherapy were defined by bill-
ing codes in the Medicare claims; surgery was classified into
conserving and nonconserving surgery types. Radiation
therapy was determined by billing codes and SEER data. All
definitions are provided in the eAppendix (Supplement).
Statistical Analysis
MatchingMethodology
Weincludedallblackpatients foreachmatch,sotheblackstudy
populationwas constant and fully representative of black pa-
tients in the SEERpopulation. Thewhite population changed
according to the variables used in the match. We created 3
matched analyses, each using 1 white patient and 1 black pa-
tient ineachmatchedpair.Thedemographicsanalysismatched
white toblackpatientsonage, yearofdiagnosis, andSEERsite;
thepresentationanalysismatchedpairs of black andwhitepa-
tients on the demographics variables as well as presentation
characteristics (comorbidconditionsand tumorbiology [stage,
size, grade, and estrogen receptor status]); and the treatment
analysis matched patients on demographics and presenta-
tion variables as well as relevant treatment variables such as
surgery, radiation therapy, and chemotherapy, as well as in-
dividual types of surgery and chemotherapy.
As has been suggested by Rubin,23-25 matching was per-
formed first, without viewing outcomes. All matching was
implemented using the PROC ASSIGN26 function in SAS, pro-
viding optimal matches that minimize the distance between
cases and controls.27 We used near-fine balance for SEER site
in the treatmentmatch.28-30Thismeant thatmatchesweregeo-
graphically balanced, with each SEER site contributing al-
most identical numbers of white and black patients (eAppen-
dix [Supplement]).
Matching on patient covariates in the presentation and
treatmentmatches also included a score predicting black race
(a propensity score), and a risk score based on a Charlson
score.31-34 The propensity scores used for the matches came
from a logistic regression of black vs white race on the vari-
ables to be controlled in the match (eAppendix [Supple-
ment]).Matching on a propensity score tends to balance vari-
ables in the score.27,35,36
Statistical Tests
For each matching variable we verified that the match bal-
anced the variables it intended to balance. We examined the
standardized difference for each matching variable, which is
themean difference between black andwhite as a fraction of
the standarddeviation (SD) beforematching.20,37,38Weaimed
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to achieve standardizeddifferencesbelow0.1 SDs.20,27,37,38We
also assessedhowcloselyweachievedbalanceusing 2-sample
randomization tests, specifically theWilcoxon rank-sum test
for each continuous covariate, Fisher exact test for each bi-
nary covariate, and a single cross-match test for all covariates
in a given match.39 The cross-match test estimates a sum-
marymeasure, upsilon (Υ) (range, 0-1), that compares the ac-
tual match to the balance obtained by complete randomiza-
tion. Υ = 0.5 suggests that thematch resembled a randomized
trial, indicatingasuccessfulmatch,whereasΥ = 0signifies that
the covariates always couldbeused toperfectly separateblack
patients fromwhitepatients—ie, a totallyunsuccessfulmatch—
andΥ > 0.5 signifiesbetterbalanceonobservedcovariates than
expected by randomization.
When testing the hypothesis of no difference in out-
comes between the matched black and white patients, the
Wilcoxon sign-rank statistic40 was used for continuous
outcomes, the McNemar statistic41 for binary outcomes,
and the Prentice-Wilcoxon statistic42,43 for survival out-
comes. When modeling survival differences over time, we
used the paired version of the Cox proportional hazards
model.44 We obtained standard errors for the white-black
paired differences in survival utilizing the bootstrap
method.45 White-to-white comparisons were made using
the same methods applied to the exterior match of nonover-
lapping white control groups.42,43,46 P ≤ .05 (2-tailed) was
considered statistically significant. All tests were performed
using SAS version 9.2 for UNIX (SAS Institute Inc)47 or R ver-
sion 2.13.1.48
Results
Quality ofMatches: Matching Results
A total of 107 273 patients were newly diagnosed with inva-
sive breast cancer over all 16 sites, including 7375 black pa-
tients and 99 898white patients fromwhom control patients
were matched. Table 1 reports the total black population and
3 white populations matched sequentially to the black popu-
lation.
The 3matchedwhite groups sequentially remove aspects
of the disparity while leaving other aspects in place so as to
developanunderstandingofhowthedisparityoccurs. In each
match, thevariables controlled in thatmatchwere closely bal-
anced, with no standardized difference ever exceeding 0.09
SDs. In a given match, unmatched variables exhibit differ-
ences that reveal aspects of thedisparity. For example, among
all black patients with breast cancer, 26% had a diagnosis of
diabetes, whereas whites matched for age, year of diagnosis,
and SEER site had amuch lower rate of diabetes (15.3%). The
presentation match then removed the difference in diabetes
andmanyother characteristics describingpatients at the time
of cancer diagnosis; eg, in the presentation match, 25.9% of
whiteshaddiabetes, similar to therateamongblacks.Thetreat-
ment match also identified whites with a similar rate of dia-
betes as blacks but also controlled for cancer treatment. Simi-
larmatching results for tumorbiologyand treatmentvariables
were also achieved.
We checked the simultaneous balance of all matched co-
variates using the cross-match test and its summarymeasure
Υ.39,49 For eachmatch, themultivariate imbalance inmatched
covariates was smaller than expected by random assignment
togroups (P > .99,Υ = 0.98 fordemographics;P > .99,Υ = 0.65
forpresentation;P > .99,Υ = 0.53 for treatment). Thus, in each
matchedsample,using thematchedcovariates to identifyblack
and white patients performed no better than chance.
Examining Treatment Differences by Race
Table 1 also reports information on differences in treatment
by race. Overall, 12.6% of black patients did not have evi-
dence of receiving any treatment for their breast cancer, com-
pared with 5.9% of whites (P < .001, black patients vs demo-
graphics-matched white patients). However, even among
whiteswho presentedwith the same patient and tumor char-
acteristics as blacks, 8.2%did not have evidence of treatment
(P < .001, blacks vs presentation-matched whites). Similarly,
among those who did receive treatment, mean time from di-
agnosis to treatmentwas longer amongblacks thanamongde-
mographics-matchedwhites, 29.2daysvs 22.5days (P < .001),
and even among whites who presented like blacks, the delay
was 22.8 days (P < .001). Blacks were alsomore likely to have
very longdelays in treatment.Whereas 5.8%of blacks did not
initiate treatmentwithin the first3months fromdiagnosis,only
2.5% of whites who presented like blacks displayed this gap
(P < .001). Chemotherapy was also different for blacks and
whites: 3.7%ofblacks receivedbothananthracyclineanda tax-
ane, comparedwith 5.0% of whitesmatched to blacks at pre-
sentation (P < .001).Blacksalso receivedbreast-conservingsur-
gery without any other treatment more often than
presentation-matched whites (8.2% vs 7.3%, P = .04).
Survival Results
Figure 1 shows the survival of black patients and the corre-
spondingwhitematched pairs for all 16 SEER sites in patients
diagnosed with breast cancer between 1991 and 2005. Me-
dian follow-up time after diagnosis for censored patientswas
7.6years (interquartile range [IQR], 5.7-10.1) forblacks; 7.8years
(IQR, 5.8-10.5) for demographics-matched whites; 7.7 years
(IQR, 5.8-10.4) for presentation-matchedwhites; and7.6 years
(IQR, 5.6-10.2) for treatment-matchedwhites. Table 2 reports
the 2- and 5-year survival differences, and median survival
time, for the black and matched white populations. The ab-
solute survival difference betweenblacks anddemographics-
matched whites at 5 years was 12.9% (P < .001).
Figure 1 also shows the white presentationmatch, repre-
sentingwhite patientswhohad the age, year of diagnosis, and
SEER site variables in the match but who also were matched
on patient characteristics including comorbid conditions and
tumorcharacteristics, including, butnot limited to, stage, size,
grade, and estrogen receptor status. The absolute difference
in 5-year survival between the presentation-matched white
populationand theblack total populationwas4.4% (P < .001).
We also observed the treatment-matched white popula-
tion, controlling all the variables in the presentationmatch as
well as specific treatments including type of surgery, radia-
tion therapy, and chemotherapy. The absolute difference in
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Table 1. Quality ofMatchesa
Variable
Black Patients
(n = 7375)
Matched White Patients, No. (%)
Treatment Match
(n = 7375)
Presentation Match
(n = 7375)
Demographics Match
(n = 7375)
All Whites
(Unmatched)
(n = 99 898)
Age at diagnosis, mean y 75.7 75.7 75.8 75.7 76.3d
Year of diagnosis, mean 1999.3 1999.3 1999.3 1999.3 1999.0d
CHF 710 (9.6) 654 (8.9) 675 (9.2) 435 (5.9)d 5785 (5.8)d
Diabetes 1917 (26.0) 1931 (26.2) 1908 (25.9) 1130 (15.3)d 12 762 (12.8)d
Stage
I 2340 (31.7) 2282 (30.9) 2380 (32.3) 3359 (45.5)d 45 482 (45.5)d
II 2429 (32.9) 2461 (33.4) 2453 (33.3) 2195 (29.8)d 29 537 (29.6)d
III 800 (10.8) 826 (11.2) 736 (10.0) 507 (6.9)d 6427 (6.4)d
IV 676 (9.2) 676 (9.2) 676 (9.2) 376 (5.1)d 5023 (5.0)d
Missing 1130 (15.3) 1130 (15.3) 1130 (15.3) 938 (12.7)d 13 429 (13.4)d
Grade
I 885 (12.0) 880 (11.9) 951 (12.9) 1304 (17.7)d 18 349 (18.4)d
II 2177 (29.5) 2205 (29.9) 2201 (29.8) 2724 (36.9)d 36 679 (36.7)d
III 2404 (32.6) 2343 (31.8) 2390 (32.4) 1813 (24.6)d 24 421 (24.4)d
IV 144 (2.0) 132 (1.8) 120 (1.6) 106 (1.4)b 1746 (1.7)
Missing 1765 (23.9) 1815 (24.6) 1713 (23.2) 1428 (19.4)d 18 703 (18.7)d
Estrogen receptor positive 3908 (53.0) 3878 (52.6) 3907 (53.0) 4759 (64.5)d 67 035 (67.1)d
Tumor size, cm
3-<4 769 (10.4) 780 (10.6) 725 (9.8) 597 (8.1)d 8098 (8.1)d
≥4 1594 (21.6) 1516 (20.6) 1511 (20.5) 863 (11.7)d 11 616 (11.6)d
Unknown 900 (12.2) 913 (12.4) 911 (12.4) 647 (8.8)d 8652 (8.7)d
Nodes, mean
Removed 7.7 7.5 8.3d 8.3d 8.2d
Positive 1.7 1.6 1.9 1.3d 1.3d
Ratio of nodes positive to
removed
0.16 0.15 0.16 0.11d 0.11d
No treatment 927 (12.6) 927 (12.6) 608 (8.2)d 433 (5.9)d 6487 (6.5)d
Mastectomy only 2221 (30.1) 2285 (31.0) 2239 (30.4) 2364 (32.1)c 32 913 (32.9)d
Breast-conserving surgery
Plus radiation only 1067 (14.5) 1095 (14.8) 1215 (16.5)d 1584 (21.5)d 20 532 (20.6)d
Surgery only (without other
treatment)
608 (8.2) 562 (7.6) 538 (7.3)b 542 (7.3)b 7553 (7.6)b
Chemotherapy
Doxorubicin, no taxane 534 (7.2) 502 (6.8) 561 (7.6) 441 (6.0)c 5341 (5.3)d
Doxorubicin + taxane 273 (3.7) 303 (4.1) 367 (5.0)d 314 (4.3) 3122 (3.1)c
Days from diagnosis to treatment,
of those who received treatment,
mean
29.2 29.0 22.8d 22.5d 22.0d
No treatment in 3 mo, %
Of those who received treatment 1300 (5.8) 1291 (5.6) 780 (2.5)d 579 (2.1)d 8444 (2.1)d
All patients 1300 (17.6) 1291 (17.5) 780 (10.6)d 579 (7.9)d 8444 (8.5)d
Abbreviation: CHF, congestive heart failure.
a The “Variable” column reports the variables controlled in some of the 3
matches but allowed to vary naturally in other matches. The 29 of a total of
140 variables used in the treatment match (which included all the variables in
the study), along with all 140 variables, are described in the eAppendix). The
“black patients” column reports themeans for all black patients in the data set.
The “Treatment Match” column reports themeans for the closest white match,
namely the treatment match (which also controls for presentation and
demographics variables); the “PresentationMatch” column also controls for
demographics variables. The “All Whites (Unmatched)” column reports data
for all whites in the data set, without control for age, year of diagnosis, or SEER
site. Results for each variable that appear to the left of the bold red vertical line
are for variables included in thematch designated by the column. For cells to
the left of the line, all P values were nonpaired P values as a test for balance,
usingWilcoxon rank-sum for continuous variables and Fisher exact test for
categorical variables; percentages or rates not displaying a P value designation
imply nonsignificant differences between blacks and whites. Results to the
right of the bold red vertical line are for variables not used in thematch
designated by the column. For cells to the right of the line (excluding the “All
Whites” column, which is always nonpaired), all P values were paired values
usingWilcoxon sign-rank for continuous variables andMcNemar test for
categorical variables; percentages or rates not displaying a P value designation
imply nonsignificant differences between blacks and whites.
bP < .05.
c P < .01.
dP < .001.
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5-year survival between the treatment-matched white popu-
lationand the total blackpopulationwas3.6%(P < .001). Com-
paring the5-year survival forwhiteswhopresented likeblacks
(ie, the whites matched to blacks on presentation and demo-
graphicvariables)withwhiteswhopresentedandwere treated
like blacks (ie, the whites matched to blacks on presentation
anddemographic variables aswell as treatmentvariables), the
absolute differencewas small (0.81%) but statistically signifi-
cant (P = .04). We further examined the causes of death de-
terminedbySEERbasedondeathcertificates for the treatment-
matchedpairs (eAppendix [Supplement]). Overall, about half
of thedeathsat5yearswerecancer related.Furthermore,about
two-thirds of thedifference in 5-yearmortality betweenblack
andwhite patients was attributable to cancer-related causes,
and one-third to noncancer causes of death.
Changes in Survival Differences Over Time
Figure 2 shows survival of all black patients and demo-
graphics-matched white patients in pairs of patients diag-
nosed in the era before the introduction of taxanes (pretax-
anes; 1991-1998) and in the era after the introduction of
taxanes (posttaxanes; 1999-2005) for just the 12 SEER sites
that collected data in both periods. Both black and matched
white survival improved slightly between eras, but the
change in the black-white difference was small and not sig-
nificantly different from zero (12.4% in the pretaxanes
period and 12.2% in the posttaxanes period; P = .65). There
also was no significant difference in the difference between
blacks and whites matched on presentation or the treatment
match between the eras before and after introduction of tax-
anes (eAppendix [Supplement]).
Table 2. Breast Cancer Outcomes for All Matchesa
Outcome Measure
Black Patients
(n = 7375)
Matched White Patients
Treatment Match
(n = 7375)
Presentation Match
(n = 7375)
Demographics Match
(n = 7375)
Survival, median
(IQR), mo
74 (71-77) 82 (79-85) 85 (82-88) 108 (104-110)
2-y survival, % (95%
CI)
76.3 (75.3-77.3) 78.1 (77.2-79.1) 79.4 (78.4-80.3) 86.0 (85.2-86.8)
White − black
difference
NA 1.8 (0.7-2.8) 3.1 (1.9-4.3) 9.7 (8.4-11.0)
P value .006 <.001 <.001
No. of deaths 1681 1569 1469 992
5-y survival, % (95%
CI)
55.9 (54.8-57.0) 59.5 (58.3-60.6) 60.3 (59.2-61.4) 68.8 (67.8-69.9)
White − black
difference
NA 3.6 (2.3-4.9) 4.4 (2.8-5.8) 12.9 (11.5-14.5)
P value <.001 <.001 <.001
No. of deaths 3207 2942 2888 2257
Paired Cox model HR,
black:white (95% CI)
NA 1.11 (1.05-1.17) 1.18 (1.12-1.24) 1.54 (1.46-1.62)
P value <.001 <.001 <.001
Abbreviations: HR, hazard ratio; IQR,
interquartile range; NA, not
applicable.
a All P values for differences in
survival between black patients and
matched white patients use the
Prentice-Wilcoxon test. Paired Cox
Model P values use all follow-up
data after diagnosis. All confidence
intervals for white-black survival
differences were based on
bootstrapped standard errors.
Figure 1. Kaplan-Meier Plot for Breast Cancer Survival for the Total Black Study Population and 3Matched
White Populations Diagnosed Between 1991-2005
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Explaining Differences in Presentation
There were large differences in the way black and white pa-
tients presented. As a secondary analysis we studied differ-
ences in primary care well before diagnosis occurred in black
and matched white populations. Table 3 describes preven-
tive care indicators between 18 months to 6 months prior to
diagnosis of breast cancer in the study’s 3matchedpairs. (See
eAppendix [Supplement] for coding definitions.) For the de-
mographics match, blacks had significantly less evidence of
at least 1 primary care visit50,51 than matched whites (80.5%
vs 88.5%, respectively; P < .001); significantly lower rates of
breast cancer screening (23.5%vs 35.7%;P < .001); and signifi-
cantly lower rates of colon cancer and cholesterol screening.
Smaller differences, still significant, were observed for pre-
sentation and treatment matches.
Examining the Relationship of Estrogen Receptor Status
to the Survival Disparity
In this analysis we have reported the demographics match
using only age, SEER site, and year of diagnosis that served as
our base case forwhichwe compared the role of presentation
and then treatment. Because presentation comprises some
variables that are potentially changeable (such as comorbid
conditions and tumor size at timeof diagnosis) and some that
are biological and should not change (such as estrogen recep-
tor status),wealsopresent a secondarymatchinganalysis that
included the demographicsmatching variables plus estrogen
receptor status (eAppendix [Supplement]). We found that
5-year survival inwhite patientsmatched to blackpatients for
demographics plus estrogen receptor status decreased from
68.8% (95%CI, 67.8%-69.9%) to 67.1% (95%CI, 66.0%-68.1%)
Table 3. Primary and Preventive Care in the 6 to 18Months Prior to Diagnosis, AcrossMatches
Measure
Black Patients
(n = 7375)
Matched White Patientsa
Treatment
Match
(n = 7375)
Presentation
Match
(n = 7375)
Demographics
Match
(n = 7375)
Any primary care
No. evaluablee 5546 5388 5168 5546
Primary care, No. (%) 4463 (80.5) 4655 (86.4)b 4496 (87.0)b 4908 (88.5)b
Any breast cancer screening
No. evaluablee 5546 5388 5168 5546
Screened, No. (%) 1304 (23.5) 1596 (29.6)b 1602 (31.0)b 1978 (35.7)b
Any cholesterol screening
No. evaluablee 5546 5388 5168 5546
Screened, No. (%) 1870 (33.7) 2024 (37.6)b 1965 (38.0)b 2116 (38.2)b
Any colon cancer screening
No. evaluablee 5546 5388 5168 5546
Screened, No. (%) 915 (16.5) 1115 (20.7)b 1101 (21.3)b 1313 (23.7)b
aFor eachmatch, pairs were only
assessed if bothmembers of the pair
had 18months of data to evaluate
prediagnosis variables. This meant
that for this table, we only analyzed
patients who were diagnosed after
age 66.5 years and diagnosed later
than July 1, 1992. The paired P values
are calculated between the black
patients andmatched white patients
using McNemar Test.
bP < .001.
Figure 2. Breast Cancer Survival for Blacks and Demographics-MatchedWhites for the Era Before
Introduction of Taxanes (Pretaxanes; 1991-1998) and the Era After Introduction of Taxanes
(Posttaxanes; 1999-2005)
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(P < .001). Hence, a portion of the survival difference be-
tween the demographics match and the presentation match
wasdue todifferences in estrogen receptor status, andas such
shouldnot be something that better screeningor primary care
could directly change, although improved preventive mea-
sures may potentially allow for earlier diagnosis.
Socioeconomic Status
As a final secondary analysis, using the treatment-matched
pairs, we fit a paired Cox model to evaluate the influence of
racebeforeandafteradjusting fordualeligibility status forboth
Medicare and Medicaid. Without adjustment, the black-vs-
white hazard ratio for death was 1.11 (95% CI, 1.05-1.17)
(P < .001). After adjusting for dual eligibility status, the haz-
ard ratiowas 1.02 (95%CI, 0.97-1.09) (P = .41). Using variables
reflectingneighborhoodpoverty andeducation (Census 2000,
databased on the patient’s census tract) we observed find-
ings similar to those obtained by adjusting for dual eligibility
(eAppendix [Supplement]).
Discussion
The large racial difference in breast cancer survival from
diagnosis did not change between 1991-1998 and 1999-2005.
Most of the difference is explained by poorer health of black
patients at diagnosis, with more advanced disease, worse
biological features of the disease, and more comorbid con-
ditions. The 5-year survival difference observed with whites
matched for demographics (age, year of presentation, and
SEER site) was 12.9%, or a difference in median survival
time of nearly 3 years, whereas with whites matched for
cancer and comorbid conditions (ie, the presentation
match) the difference was 4.4%, or a median survival differ-
ence of less than 1 year. Compared with whites who both
presented like blacks and were treated like blacks, (ie, the
treatment match), the difference only changed by 3.6%;
hence, treatment differences explained only 0.81% of the
12.9% difference in 5-year survival. Treatment disparities
might matter more if blacks were diagnosed with less
advanced cancers.
The 3.6% remaining racial difference in 5-year survival
after matching on treatment was predominantly can-
cer related (eAppendix [Supplement]). However, given
that racial and income disparities are seen throughout the
US health care system,52 it would have been surprising to
observe a complete elimination of the survival difference by
matching for similar cancer presentation and treatment.
One important strengthofour studywas that99 898white
patients were used as potential controls for 7375 black pa-
tients. This allowed us to achieve very close matches, gener-
ally avoiding the need formodel-based analyses. Amodel fit-
ted to 99 898 whites and 7375 blacks would be a model that
mostly describes what happens to whites.53
There were important limitations to this study. We did
not have chart review to verify our definitions of treatment
coded from Medicare bills or noted in SEER data. Hence, for
example, we could not track the use of tamoxifen, although
other studies have suggested that black patients use
tamoxifen in at least as high a rate as white patients when
they have estrogen receptor–positive tumors.54-57 Neverthe-
less, it is possible that some portion of the residual unex-
plained difference after accounting for presentation and
treatment relates to endocrine therapy not tracked in SEER.
Furthermore, using SEER data we could not define triple-
negative tumors.58 However, triple-negative tumors are
less common in postmenopausal than premenopausal
blacks (14% vs 39%), and postmenopausal blacks and whites
display no difference in their rates of triple-negative
tumors.58
Our results suggest that itmaybedifficult to eliminate the
racial disparity in survival from diagnosis unless differences
inpresentationcanbereduced.There isalsoadisparity in treat-
ment, with blacks receiving treatment inferior to that re-
ceived by whites with similar presentation, but this explains
only a small part of the observed difference in survival. The
disparity in treatmentmightmattermore if thedisparity inpre-
sentation were reduced, because blacks would then be diag-
nosedwith less advanceddisease, forwhich treatment ismore
effective.
Whether better screening for breast cancer would
reduce the disparity in presentation is not known. Our data
provide evidence suggesting that black patients diagnosed
with breast cancer had previously received less adequate
primary care than did white patients in the demographics
match. Also, blacks were diagnosed with more advanced-
stage disease and also with larger tumors. If a woman has
limited primary care, then apart from screening, it may take
longer before she seeks medical attention for a lump in her
breast. Our data cannot distinguish the effects of screening
from the effects of greater access to primary care. Screening
and earlier diagnosis might be ineffective if black patients
and white patients with similar cancer biology as measured
by SEER had very different cancer biology if measured in
much greater detail; however, in our population of elderly
Medicare patients, differences in biology are smaller issues
than in premenopausal patients.
Black patients are diagnosed not only with more ad-
vanced breast cancers but also with more unrelated comor-
bid conditions. Someof the effectiveness of cancer treatment
for blacksmaybebluntedbyother health problems. If thedif-
ferences in comorbid conditions at diagnosiswere reduced, it
is possible that thedifferences in cancer treatmentwouldmat-
ter more for the differences in survival.
Conclusions
In the SEER-Medicare database, racial differences in breast
cancer survival did not substantially change among women
diagnosed between 1991 and 2005. These differences in
survival appear primarily related to presentation character-
istics at diagnosis rather than treatment differences. In
the presence of large racial differences in patient character-
istics at presentation, treatment differences explained
only a small portion of the survival difference, because
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white women who presented like black women (ie, were
matched on demographics and presentation) but who
received treatment similar to that received by white women
fared almost the same as white women who presented like
black women and who were treated in the same way as
black women.
ARTICLE INFORMATION
Author Affiliations: Center for Outcomes
Research, The Children’s Hospital of Philadelphia,
Philadelphia, Pennsylvania (Silber, Ross, Teng,
WangM, Niknam, Ludwig, WangW, Even-Shoshan);
Leonard andMadlyn Abramson Cancer Center of
the University of Pennsylvania, Philadelphia (Silber,
Clark, Giantonio, Fox); Departments of Pediatrics,
University of Pennsylvania Perelman School of
Medicine, Philadelphia, and Division of Pediatric
Oncology, The Children’s Hospital of Philadelphia
(Silber); Department of Anesthesiology and Critical
Care, University of Pennsylvania Perelman School
of Medicine (Silber); Department of Health Care
Management, TheWharton School, University of
Pennsylvania (Silber); The Leonard Davis Institute
of Health Economics, University of Pennsylvania
(Silber, Rosenbaum, Even-Shoshan); Department of
Statistics, TheWharton School (Rosenbaum);
Division of Medical Oncology, the Hospital of the
University of Pennsylvania, Philadelphia, and
Department of Medicine, University of
Pennsylvania Perelman School of Medicine (Clark,
Giantonio, Fox).
Author Contributions:Dr Silber had full access to
all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the
data analysis.
Study concept and design: Silber, Rosenbaum, Clark,
Giantonio, Fox.
Acquisition of data: Silber, Even-Shoshan, Fox.
Analysis and interpretation of data: Silber,
Rosenbaum, Clark, Ross, Teng, M.Wang, Niknam,
Ludwig, W.Wang, Fox.
Drafting of the manuscript: Silber, Rosenbaum,
Clark, Ross.
Critical revision of the manuscript for important
intellectual content: Silber, Rosenbaum, Clark,
Giantonio, Teng, M.Wang, Niknam, Ludwig, W.
Wang, Even-Shoshan, Fox.
Statistical analysis: Silber, Rosenbaum, Ross, Teng,
Ludwig, W.Wang.
Obtained funding: Silber, Rosenbaum,
Even-Shoshan.
Administrative, technical, or material support: Clark,
M. Wang, Niknam, Even-Shoshan.
Study supervision: Silber, Rosenbaum,
Even-Shoshan, Fox.
Conflict of Interest Disclosures:All authors have
completed and submitted the ICMJE Form for
Disclosure of Potential Conflicts of Interest and
none were reported.
Funding/Support: This research was funded
through a grant from the Agency for Healthcare
Research and Quality (AHRQ), Department of
Health and Human Services (R01 HS 018355), and
by the US National Science Foundation (NSF SBS
1260782). This study used the linked
SEER-Medicare database.
Role of the Sponsor: The AHRQ and the US
National Science Foundation had no role in the
design and conduct of the study; the collection,
management, analysis, and interpretation of the
data; the preparation, review, or approval of the
manuscript; or the decision to submit the
manuscript for publication.
Disclaimer: The findings and conclusions of this
report are those of the authors and do not
necessarily represent the official position of the
AHRQ.
Additional Contributions:We thank Traci Frank,
AA, Hong Zhou, MS, Philip Saynisch, BA, and
Alexander Hill, BS (Center for Outcomes Research,
The Children’s Hospital of Philadelphia,
Philadelphia, Pennsylvania), for their assistance
with this research. None of these individuals
received compensation apart from salary for their
contributions. We also acknowledge the efforts of
the Applied Research Program, National Cancer
Institute; the Office of Research, Development and
Information, Centers for Medicare &Medicaid
Services; InformationManagement Services Inc;
and the Surveillance, Epidemiology and End Results
(SEER) Program tumor registries in the creation of
the SEER-Medicare database.
REFERENCES
1. Haas JS, Earle CC, Orav JE, et al. Racial
segregation and disparities in breast cancer care
andmortality. Cancer. 2008;113(8):2166-2172.
2. Ward E, Jemal A, Cokkinides V, et al. Cancer
disparities by race/ethnicity and socioeconomic
status. CA Cancer J Clin. 2004;54(2):78-93.
3. Gorey KM, Luginaah IN, Schwartz KL, et al.
Increased racial differences on breast cancer care
and survival in America: historical evidence
consistent with a health insurance hypothesis,
1975-2001. Breast Cancer Res Treat. 2009;113(3):
595-600.
4. Grann V, Troxel AB, Zojwalla N, Hershman D,
Glied SA, Jacobson JS. Regional and racial
disparities in breast cancer-specific mortality. Soc
Sci Med. 2006;62(2):337-347.
5. Curtis E, Quale C, HaggstromD, Smith-Bindman
R. Racial and ethnic differences in breast cancer
survival: howmuch is explained by screening,
tumor severity, biology, treatment, comorbidities,
and demographics? Cancer. 2008;112(1):171-180.
6. Ooi SL, Martinez ME, Li CI. Disparities in breast
cancer characteristics and outcomes by
race/ethnicity. Breast Cancer Res Treat. 2011;127(3):
729-738.
7. Cross CK, Harris J, Recht A. Race, socioeconomic
status, and breast carcinoma in the U.S: what have
we learned from clinical studies. Cancer.
2002;95(9):1988-1999.
8. Smith-Bindman R, Miglioretti DL, Lurie N, et al.
Does utilization of screeningmammography
explain racial and ethnic differences in
breast cancer? Ann Intern Med. 2006;144(8):
541-553.
9. McCarthy EP, Burns RB, Coughlin SS, et al.
Mammography use helps to explain differences in
breast cancer stage at diagnosis between older
black and white women. Ann Intern Med.
1998;128(9):729-736.
10. Tammemagi CM, Nerenz D, Neslund-Dudas C,
Feldkamp C, Nathanson D. Comorbidity and
survival disparities among black and white patients
with breast cancer. JAMA. 2005;294(14):1765-1772.
11. Chagpar AB, Crutcher CR, Cornwell LB,
McMasters KM. Primary tumor size, not race,
determines outcomes in womenwith
hormone-responsive breast cancer. Surgery.
2011;150(4):796-801.
12. McBride R, Hershman D, Tsai WY, Jacobson JS,
Grann V, Neugut AI. Within-stage racial differences
in tumor size and number of positive lymph nodes
in womenwith breast cancer. Cancer. 2007;110(6):
1201-1208.
13. Hershman D, McBride R, Jacobson JS, et al.
Racial disparities in treatment and survival among
womenwith early-stage breast cancer. J Clin Oncol.
2005;23(27):6639-6646.
14. Gorin SS, Heck JE, Cheng B, Smith SJ. Delays in
breast cancer diagnosis and treatment by
racial/ethnic group. Arch Intern Med.
2006;166(20):2244-2252.
15. Byers TE, Wolf HJ, Bauer KR, et al; Patterns of
Care Study Group. The impact of socioeconomic
status on survival after cancer in the United States:
findings from the National Program of Cancer
Registries Patterns of Care Study. Cancer.
2008;113(3):582-591.
16. Warren JL, Klabunde CN, Schrag D, Bach PB,
Riley GF. Overview of the SEER-Medicare data:
content, research applications, and generalizability
to the United States elderly population.Med Care.
2002;40(8)(suppl):IV-3-IV-18.
17. SEER-Medicare Linked Database. National
Cancer Institute website. http://healthservices
.cancer.gov/seermedicare. Accessed August 8,
2012.
18. Bach PB, Guadagnoli E, Schrag D, Schussler N,
Warren JL. Patient demographic and
socioeconomic characteristics in the
SEER-Medicare database applications and
limitations.Med Care. 2002;40(8)(suppl):
IV-19-IV-25.
19. Silber JH, Rosenbaum PR, Kelz RR, et al.
Medical and financial risks associated with surgery
in the elderly obese. Ann Surg. 2012;256(1):79-86.
20. Silber JH, Rosenbaum PR, TrudeauME, et al.
Multivariate matching and bias reduction in the
surgical outcomes study.Med Care. 2001;39(10):
1048-1064.
21. Volpp KG, Rosen AK, Rosenbaum PR, et al.
Mortality among hospitalizedMedicare
beneficiaries in the first 2 years following ACGME
resident duty hour reform. JAMA. 2007;298(9):
975-983.
22. Volpp KG, Rosen AK, Rosenbaum PR, et al.
Mortality among patients in VA hospitals in the first
2 years following ACGME resident duty hour
reform. JAMA. 2007;298(9):984-992.
23. Rubin DB. For objective causal inference,
design trumps analysis. Ann Appl Stat. 2008;2(3):
808-840.
Research Original Investigation Black andWhiteWomenWith Breast Cancer
396 JAMA July 24/31, 2013 Volume 310, Number 4 jama.com
Downloaded From: http://jama.jamanetwork.com/ by a University of Maryland User  on 07/24/2013
24. Rubin DB. The design versus the analysis of
observational studies for causal effects: parallels
with the design of randomized trials. Stat Med.
2007;26(1):20-36.
25. Rubin DB. Using propensity scores to help
design obserational studies: application to the
tobacco litigation.Health Serv Outcomes Res
Methodol. 2001;2(3-4):169-188.
26. SAS Institute Inc. SAS/OR User’s Guide:
Mathematical Programming (Version 8). Cary, NC:
SAS Institute Inc; 1999:39-54.
27. Rosenbaum PR. Design of Observational
Studies.New York, NY: Springer; 2010.
28. Rosenbaum PR, Ross RN, Silber JH. Minimum
distancematched sampling with fine balance in an
observational study of treatment for ovarian
cancer. J Am Stat Assoc. 2007;102(477):75-83.
29. Yang D, Small DS, Silber JH, Rosenbaum PR.
Optimal matching with minimal deviation from fine
balance in a study of obesity and surgical outcomes.
Biometrics. 2012;68(2):628-636.
30. Rosenbaum PR. Design of Observational
Studies.New York, NY: Springer; 2010:197-206.
31. CharlsonME, Pompei P, Ales KL, MacKenzie CR.
A newmethod of classifying prognostic
comorbidity in longitudinal studies: development
and validation. J Chronic Dis. 1987;40(5):373-383.
32. Deyo RA, Cherkin DC, Ciol MA. Adapting a
clinical comorbidity index for use with ICD-9-CM
administrative databases. J Clin Epidemiol.
1992;45(6):613-619.
33. Klabunde CN, Legler JM,Warren JL, Baldwin
LM, Schrag D. A refined comorbidity measurement
algorithm for claims-based studies of breast,
prostate, colorectal, and lung cancer patients. Ann
Epidemiol. 2007;17(8):584-590.
34. Klabunde CN, Potosky AL, Legler JM,Warren
JL. Development of a comorbidity index using
physician claims data. J Clin Epidemiol.
2000;53(12):1258-1267.
35. Rosenbaum P, Rubin D. The central role of the
propensity score in observational studies for causal
effects. Biometrika. 1983;70(1):41-55.
36. Joffe MM, Rosenbaum PR. Invited
commentary: propensity scores. Am J Epidemiol.
1999;150(4):327-333.
37. Rosenbaum PR, Rubin DB. Constructing a
control group usingmultivariate matched sampling
methods that incorporate the propensity score. Am
Stat. 1985;39(1):33-38.
38. CochranWG, Rubin DB. Controlling bias in
observational studies: a review. Sankhyā. 1973;35:
417-446.
39. Heller R, Rosenbaum PR, Small D. Using the
cross-match test to appraise covariate balance in
matched pairs. Am Stat. 2010;64(4):299-309.
40. Hollander M,Wolfe DA.Nonparametric
Statistical Methods. 2nd ed. New York, NY: John
Wiley & Sons; 1999.
41. Bishop YMM, Fienberg SE, Holland PW. Discrete
Multivariate Analysis: Theory and Practice.
Cambridge: MIT Press; 1975:281-286.
42. Kalbfleish JD, Prentice RL. The Statistical
Analysis of Failure Time Data.New York, NY: John
Wiley; 1980.
43. O’Brien PC, Fleming TR. A paired
Prentice-Wilcoxon test for censored paired data.
Biometrics. 1987;43(1):169-180.
44. Holt J, Prentice R. Survival analysis in twin
studies andmatched pair experiments. Biometrika.
1974;61(1):17-30.
45. Efron B, Tibshirani R. Bootstrapmethods for
standard errors, confidence intervals, and other
measures of statistical accuracy. Stat Sci. 1986;1(1):
54-75.
46. Rosenbaum PR, Silber JH. Using the exterior
match to compare two entwinedmatched control
groups. Am Stat. 2013;67(2):67-75.
47. Statistical Analytic Software System for UNIX
(Version 9.2). Cary, NC: SAS Institute Inc; 2009.
48. R Development Core Team. R: A Language and
Environment for Statistical Computing.
R Foundation for Statistical Computing
website. www.R-project.org. 2012. AccessedMay
14, 2013.
49. Rosenbaum PR. An exact distribution-free test
comparing twomultivariate distributions based on
adjacency. J R Stat Soc B. 2005;67(part 4):515-530.
50. PhamHH, Schrag D, O’Malley AS, Wu B, Bach
PB. Care patterns in Medicare and their implications
for pay for performance. N Engl J Med.
2007;356(11):1130-1139.
51. Bach PB, PhamHH, Schrag D, Tate RC,
Hargraves JL. Primary care physicians who treat
blacks and whites. N Engl J Med. 2004;351(6):
575-584.
52. 2011 National Healthcare Quality and
Disparities Reports. Agency for Healthcare
Research and Quality website. www.ahrq.gov
/research/findings/nhqrdr/nhqrdr11/qrdr11.html.
2011. Accessed November 12, 2012.
53. Daniel SR, Armstrong K, Silber JH, et al. An
algorithm for optimal taperedmatching, with
application to disparities in survival. J Comput
Graph Stat. 2008;17(4):914-924.
54. Hershman DL, Kushi LH, Shao T, et al. Early
discontinuation and nonadherence to adjuvant
hormonal therapy in a cohort of 8,769 early-stage
breast cancer patients. J Clin Oncol. 2010;28(27):
4120-4128.
55. Kimmick G, Anderson R, Camacho F, Bhosle M,
HwangW, Balkrishnan R. Adjuvant hormonal
therapy use among insured, low-incomewomen
with breast cancer. J Clin Oncol. 2009;27(21):
3445-3451.
56. Ma AM, Barone J, Wallis AE, et al.
Noncompliance with adjuvant radiation,
chemotherapy, or hormonal therapy in
breast cancer patients. Am J Surg. 2008;196(4):
500-504.
57. Owusu C, Buist DS, Field TS, et al. Predictors of
tamoxifen discontinuation among older women
with estrogen receptor–positive breast cancer.
J Clin Oncol. 2008;26(4):549-555.
58. Carey LA, Perou CM, Livasy CA, et al. Race,
breast cancer subtypes, and survival in the Carolina
Breast Cancer Study. JAMA. 2006;295(21):
2492-2502.
Black andWhiteWomenWith Breast Cancer Original Investigation Research
jama.com JAMA July 24/31, 2013 Volume 310, Number 4 397
Downloaded From: http://jama.jamanetwork.com/ by a University of Maryland User  on 07/24/2013
